Cybin (HELP) Research & Development (2020 - 2026)
Cybin's (HELP) quarterly Research & Development came in at $28.9 million in Q1 2026, down 24.47% YoY from $38.2 million in Q1 2025, and up 21.08% on a QoQ basis from $23.9 million in Q4 2025.
Cybin (HELP) Research & Development (2020 - 2026) Analysis & Trends
Cybin (HELP) has 7 years of Research & Development data on file, last reported at $28.9 million in Q1 2026.
- Quarterly Research & Development fell 24.47% year-over-year to $28.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86.6 million (up 48.35% YoY) and the FY2026 annual result came in at $86.6 million, up 120.83% from the prior year.
- Research & Development improved to $28.9 million in Q1 2026, from $23.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $38.2 million in Q1 2025 to a low of -$278040.9 in Q1 2023.
- A 5-year average of $10.3 million and a median of $4.8 million in 2023 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 245772.7% in 2024, down 99.83% in 2024.
- Tracing HELP's Research & Development over 5 years: stood at $6256.0 in 2022, then decreased by 12.66% to $5464.2 in 2023, then surged by 245772.7% to $13.4 million in 2024, then jumped by 77.57% to $23.9 million in 2025, then increased by 21.08% to $28.9 million in 2026.
- The last three Research & Development figures came in at $28.9 million (Q1 2026), $23.9 million (Q4 2025), and $18.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Cybin | 417.29 Mn | 417.29 Mn | - | 28.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.89 Mn |
| Dec 31, 2025 | 23.86 Mn |
| Sep 30, 2025 | 18.85 Mn |
| Jun 30, 2025 | 15.00 Mn |
| Mar 31, 2025 | 38.24 Mn |
| Dec 31, 2024 | 13.44 Mn |
| Sep 30, 2024 | 6.68 Mn |
| Jun 30, 2024 | 8,041.00 |
| Mar 31, 2024 | 24.00 Mn |
| Dec 31, 2023 | 5,464.21 |
| Sep 30, 2023 | 4,994.75 |
| Jun 30, 2023 | 4.75 Mn |
| Feb 28, 2023 | -278,040.91 |
| Dec 31, 2022 | 6,256.00 |
| Sep 30, 2022 | 5,141.00 |
| May 31, 2022 | 1.64 Mn |
| Mar 31, 2022 | 5,829.00 |
| Dec 31, 2021 | 4,963.00 |
| Sep 30, 2021 | 3.03 Mn |
| Jun 30, 2021 | 2,421.06 |